Alexandria  Forbes net worth and biography

Alexandria Forbes Biography and Net Worth

CEO of MeiraGTx
Dr. Alexandria Forbes has served as our President, Chief Executive Officer and a member of our board of directors since March 2015. Prior to joining MeiraGTx, Dr. Forbes served as Senior Vice President of Commercial Operations at Kadmon Holdings, Inc., a biopharmaceutical company, from September 2013 to April 2015. Prior to Kadmon Holdings, Inc., Dr. Forbes spent eleven years as a healthcare investor at Sivik Global Healthcare, a healthcare hedge fund, from September 2000 to November 2008, and at Meadowvale Asset Management, a healthcare hedge fund, from January 2010 to June 2012. Before entering the hedge fund industry, Dr. Forbes was a Human Frontiers/Howard Hughes postdoctoral fellow at the Skirball Institute of Biomolecular Medicine at NYU Langone Medical Center from March 1997 to September 2000. Prior to this, Dr. Forbes was a research fellow at Duke University, and also at the Carnegie Institute at Johns Hopkins University. Dr. Forbes received an M.A. in Natural Sciences from Cambridge University and a Ph.D. in Molecular Genetics from Oxford University.

What is Alexandria Forbes' net worth?

The estimated net worth of Alexandria Forbes is at least $10.31 million as of January 7th, 2025. Dr. Forbes owns 1,395,102 shares of MeiraGTx stock worth more than $10,309,804 as of March 28th. This net worth approximation does not reflect any other investments that Dr. Forbes may own. Additionally, Dr. Forbes receives a salary of $2,890,000.00 as CEO at MeiraGTx. Learn More about Alexandria Forbes' net worth.

How old is Alexandria Forbes?

Dr. Forbes is currently 59 years old. There are 5 older executives and no younger executives at MeiraGTx. Learn More on Alexandria Forbes' age.

What is Alexandria Forbes' salary?

As the CEO of MeiraGTx Holdings plc, Dr. Forbes earns $2,890,000.00 per year. Learn More on Alexandria Forbes' salary.

How do I contact Alexandria Forbes?

The corporate mailing address for Dr. Forbes and other MeiraGTx executives is 450 East 29thStreet 14thFloor, NEW YORK NY, 10016. MeiraGTx can also be reached via phone at (646) 860-7985 and via email at investors@meiragtx.com. Learn More on Alexandria Forbes' contact information.

Has Alexandria Forbes been buying or selling shares of MeiraGTx?

During the last quarter, Alexandria Forbes has sold $231,878.33 of MeiraGTx stock. Most recently, Alexandria Forbes sold 35,839 shares of the business's stock in a transaction on Tuesday, January 7th. The shares were sold at an average price of $6.47, for a transaction totalling $231,878.33. Following the completion of the sale, the chief executive officer now directly owns 1,395,102 shares of the company's stock, valued at $9,026,309.94. Learn More on Alexandria Forbes' trading history.

Who are MeiraGTx's active insiders?

MeiraGTx's insider roster includes Alexandria Forbes (CEO), Richard Giroux (CFO), and Stuart Naylor (Insider). Learn More on MeiraGTx's active insiders.

Are insiders buying or selling shares of MeiraGTx?

During the last twelve months, MeiraGTx insiders bought shares 1 times. They purchased a total of 1,250,000 shares worth more than $5,000,000.00. During the last twelve months, insiders at the sold shares 2 times. They sold a total of 59,839 shares worth more than $382,838.33. The most recent insider tranaction occured on January, 21st when CFO Richard Giroux sold 24,000 shares worth more than $150,960.00. Insiders at MeiraGTx own 8.4% of the company. Learn More about insider trades at MeiraGTx.

Information on this page was last updated on 1/21/2025.

Alexandria Forbes Insider Trading History at MeiraGTx

See Full Table

Alexandria Forbes Buying and Selling Activity at MeiraGTx

This chart shows Alexandria Forbes's buying and selling at MeiraGTx by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$232ksoldQ1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1-$200k-$100k$0$100k$200kTotal Insider BuyingTotal Insider Selling

MeiraGTx Company Overview

MeiraGTx logo
MeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases, neurodegenerative diseases, and xerostomia. Its programs in clinical development include Phase I/II clinical stage programs in achromatopsia, X-linked retinitis pigmentosa, and RPE65-deficiency; Phase I clinical trials for radiation-induced xerostomia; and Parkinson's program that has completed a Phase II trial. It has a research collaboration agreement with Janssen Pharmaceuticals, Inc. for the research, development, and commercialization of gene therapies for the treatment of inherited retinal disease. The company was incorporated in 2015 and is based in New York, New York.
Read More

Today's Range

Now: $7.39
Low: $7.16
High: $7.48

50 Day Range

MA: $6.81
Low: $6.04
High: $8.25

2 Week Range

Now: $7.39
Low: $3.85
High: $8.75

Volume

444,192 shs

Average Volume

278,637 shs

Market Capitalization

$582.74 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.23